New antihypertensives

Here are some new antihypertensives that have been approved or are in development:

  1. Lorcaserin (Belviq): A selective serotonin receptor agonist that was approved in 2013 for weight loss, but has also been shown to have antihypertensive effects.
  2. Rasilez (Aliskiren): A direct renin inhibitor that was approved in 2007, but has been shown to have additional benefits in reducing blood pressure and cardiovascular events.
  3. Amiloride (Midodrine): A potassium-sparing diuretic that was approved in 2014 for the treatment of orthostatic hypotension, but has also been shown to have antihypertensive effects.
  4. Vasopressin receptor antagonists: A class of medications that are being developed to treat hypertension by blocking the action of vasopressin, a hormone that constricts blood vessels.
  5. SGLT2 inhibitors: A class of medications that are being developed to treat type 2 diabetes, but have also been shown to have antihypertensive effects by increasing sodium excretion and reducing blood pressure.
  6. Calcium channel blockers: A class of medications that are being developed to treat hypertension by blocking the entry of calcium into smooth muscle cells, which relaxes blood vessels and reduces blood pressure.
  7. Nitric oxide donors: A class of medications that are being developed to treat hypertension by releasing nitric oxide, a molecule that relaxes blood vessels and reduces blood pressure.
  8. Angiotensin receptor-neprilysin inhibitors: A class of medications that are being developed to treat hypertension by blocking the action of angiotensin II and neprilysin, an enzyme that breaks down atrial natriuretic peptide, a hormone that relaxes blood vessels.
  9. CGRP receptor antagonists: A class of medications that are being developed to treat hypertension by blocking the action of calcitonin gene-related peptide (CGRP), a hormone that constricts blood vessels.
  10. TRPV1 antagonists: A class of medications that are being developed to treat hypertension by blocking the action of transient receptor potential vanilloid 1 (TRPV1), a receptor that is involved in the regulation of blood pressure.

Some of the new antihypertensives that are in development include:

  1. BAY 94-8862: A novel angiotensin receptor-neprilysin inhibitor that is being developed by Bayer.
  2. LCZ696: A novel angiotensin receptor-neprilysin inhibitor that is being developed by Novartis.
  3. FINerenone: A novel potassium-sparing diuretic that is being developed by Bayer.
  4. AZD1236: A novel SGLT2 inhibitor that is being developed by AstraZeneca.
  5. BAY 1121782: A novel TRPV1 antagonist that is being developed by Bayer.

It's worth noting that the development of new antihypertensives is an ongoing process, and new medications are being developed and approved all the time.